Extrapulmonary effects of maintenance corticosteroid therapy with alternate-day prednisone and inhaled beclomethasone in children with chronic asthma.
Extrapulmonary effects of alternate-day prednisone and inhaled beclomethasone dipropionate therapy were examined in 24 and 32 children with asthma, respectively. Early morning serum cortisol values were significantly lower among patients receiving alternate-day prednisone than among patients receiving inhaled beclomethasone dipropionate and control subjects at 24 hours but not at 48 hours after an alternate-day prednisone dose. Urinary-free cortisol output during the second 24 hours of the alternate-day prednisone regimen were similar to values among patients receiving inhaled beclomethasone and were significantly lower than among control subjects for both groups. Mean heights among patients before being placed on maintenance corticosteroids were at the thirty-fifth percentile and were similar for both regimens. This was significantly lower than initial measurements for control subjects who, on average, were near the fiftieth percentile for both children with asthma not requiring maintenance corticosteroids and normal healthy Iowa children. Mean heights for both corticosteroid-treated groups remained at the thirty-fifth percentile after more than a 2-year average duration of follow-up. Heights of children with chronic asthma not requiring maintenance corticosteroids were initially significantly higher (fifty-first percentile) than the patients who subsequently required maintenance corticosteroids and increased significantly to the sixty-first percentile during a mean 2.7-year follow-up. Heights of healthy Iowa children remained near the fiftieth percentile during a mean 7-year follow-up. Disproportionate weight gain, although it was not consistently present, was significantly more likely with the alternate-day prednisone. Other extrapulmonary effects of the corticosteroid regimens appeared not to be of clinical importance during the time period of the study.
Nassif
E
E
Department of Pediatrics, University of Iowa, Iowa City 52242.
Weinberger
M
M
Sherman
B
B
Brown
K
K
D000280:Administration, Inhalation; D000293:Adolescent; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects*; D001772:Blood Cell Count; D001827:Body Height / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002177:Candidiasis / Q000209:etiology; D002386:Cataract / Q000139:chemically induced; D002648:Child; D005260:Female; D006128:Growth / Q000187:drug effects; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000652:urine; D007136:Immunoglobulins / Q000032:analysis; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects*
D006454:Hemoglobins; D007136:Immunoglobulins; D001507:Beclomethasone; D011241:Prednisone; D006854:Hydrocortisone